Overview

The Impact of Dupilumab on Quality of Life in Moderate to Severe Atopic Dermatitis Patients

Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
This is a single-arm, open-label study, which will examine the effect of dupilumab on quality of life in atopic dermatitis patients.
Phase:
Phase 4
Details
Lead Sponsor:
University of California, San Francisco
Collaborator:
Regeneron Pharmaceuticals
Treatments:
Antibodies, Monoclonal